Details

Autor(en) / Beteiligte

• Palmerini, Emanuela
• Sanfilippo, Roberta
• Grignani, Giovanni
• Buonadonna, Angela
• Romanini, Antonella
• Badalamenti, Giuseppe
• Ferraresi, Virginia
• Vincenzi, Bruno
• Comandone, Alessandro
• Pizzolorusso, Antonio
• Brunello, Antonella
• Gelsomino, Fabio
• Pas, Tommaso De
• Ibrahim, Toni
• Grosso, Federica
• Zanelli, Francesca
• Pantaleo, Maria Abbondanza
• Milesi, Laura
• Ciuffreda, Libero
• Ferrari, Vittorio
• Marchesi, Emanuela
• Quattrini, Irene
• Righi, Alberto
• Setola, Elisabetta
• Carretta, Elisa
• Picci, Piero
• Ferrari, Stefano

Titel

Trabectedin for Patients with Advanced Soft Tissue Sarcoma: A Non-Interventional, Retrospective, Multicenter Study of the Italian Sarcoma Group

Ist Teil von

• Cancers, 2021-03, Vol.13 (5), p.1053

Ort / Verlag

Switzerland: MDPI AG

Erscheinungsjahr

2021

Link zum Volltext

Quelle

EZB Free E-Journals

Beschreibungen/Notizen

• The Italian Sarcoma Group performed this retrospective analysis of patients with advanced soft tissue sarcoma, pretreated with ≥1 anthracycline-based treatment, and treated with trabectedin every three weeks. Primary endpoint was to describe real-life use of trabectedin across Italy. Secondary endpoints included objective response rate (ORR) and safety. Overall, 512 patients from 20 Italian centers were evaluated. Leiomyosarcoma (37.7%)/liposarcoma (30.3%) were the most prevalent histological types (abbreviated as L-sarcoma). Patients received a median of four trabectedin cycles (range: 1-40), mostly as a second-line treatment (~60% of patients). The ORR was 13.7% superior ( < 0.0001) in patients with L-sarcoma compared with patients with non-L-sarcoma (16.6% vs. 9.0%). Median progression-free survival (PFS) was 5.1 months, whereas median overall survival (OS) was 21.6 months. Significantly better PFS and OS were observed in patients with L-sarcoma, those with objective responses and/or disease stabilization, treated in an early line and treated with reduced dose. Bone marrow toxicity (61.4%) and transaminase increases (21.9%) were the most common grade 3/4 adverse events. The results of this real-life study suggest that trabectedin is an active treatment, which is mostly given as a second-line treatment to patients with a good performance status and high-grade, metastatic L-sarcoma (clinical trial information: NCT02793050).